Shire just nabbed FDA panel backing for prucalopride, aiming to challenge Allergan and Synergy in the chronic constipation market—and to add blockbuster sales to a portfolio that’s at the heart of Takeda’s $62 billion buyout.
Faced with a steep decline in its own profits in the last quarter, Takeda will have been looking for good numbers from acquisition target Shire – and on the whole the UK-listed firm didn’t disappoint.
Shire’s prucalopride is being assessed by regulators in the US as a treatment for chronic idiopathic constipation (CIC).
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 April 2015
Market Place
Share
Share
